Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;11(1):110-120.
doi: 10.1007/s40615-022-01502-4. Epub 2023 Jan 18.

Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA

Wilfredo R Matias #  1   2   3 , Isabel R Fulcher #  4   5 , Sara M Sauer  4 , Cody P Nolan  6 , Yodeline Guillaume  7 , Jack Zhu  7 , Francisco J Molano  7 , Elizabeth Uceta  7 , Shannon Collins  7 , Damien M Slater  8 , Vanessa M Sánchez  8 , Serina Moheed  8 , Jason B Harris  8   9 , Richelle C Charles  8   10 , Ryan M Paxton  11 , Sean F Gonsalves  11 , Molly F Franke  4 , Louise C Ivers  8   7   4   12
Affiliations

Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA

Wilfredo R Matias et al. J Racial Ethn Health Disparities. 2024 Feb.

Abstract

Objectives: Uncovering and addressing disparities in infectious disease outbreaks require a rapid, methodical understanding of local epidemiology. We conducted a seroprevalence study of SARS-CoV-2 infection in Holyoke, Massachusetts, a majority Hispanic city with high levels of socio-economic disadvantage to estimate seroprevalence and identify disparities in SARS-CoV-2 infection.

Methods: We invited 2000 randomly sampled households between 11/5/2020 and 12/31/2020 to complete questionnaires and provide dried blood spots for SARS-CoV-2 antibody testing. We calculated seroprevalence based on the presence of IgG antibodies using a weighted Bayesian procedure that incorporated uncertainty in antibody test sensitivity and specificity and accounted for household clustering.

Results: Two hundred eighty households including 472 individuals were enrolled. Three hundred twenty-eight individuals underwent antibody testing. Citywide seroprevalence of SARS-CoV-2 IgG was 13.1% (95% CI 6.9-22.3) compared to 9.8% of the population infected based on publicly reported cases. Seroprevalence was 16.1% (95% CI 6.2-31.8) among Hispanic individuals compared to 9.4% (95% CI 4.6-16.4) among non-Hispanic white individuals. Seroprevalence was higher among Spanish-speaking households (21.9%; 95% CI 8.3-43.9) compared to English-speaking households (10.2%; 95% CI 5.2-18.0) and among individuals in high social vulnerability index (SVI) areas based on the CDC SVI (14.4%; 95% CI 7.1-25.5) compared to low SVI areas (8.2%; 95% CI 3.1-16.9).

Conclusions: The SARS-CoV-2 IgG seroprevalence in a city with high levels of social vulnerability was 13.1% during the pre-vaccination period of the COVID-19 pandemic. Hispanic individuals and individuals in communities characterized by high SVI were at the highest risk of infection. Public health interventions should be designed to ensure that individuals in high social vulnerability communities have access to the tools to combat COVID-19.

Keywords: Antibodies; COVID-19; Disparities; SARS-CoV-2; Seroprevalence; Serosurvey.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study participant flow diagram
See this image and copyright information in PMC

References

    1. Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021;4(11):e2134147. doi: 10.1001/jamanetworkopen.2021.34147. - DOI - PMC - PubMed
    1. Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19–related infections, hospitalizations, and deaths. Ann Intern Med. 2020;174(3):362–373. doi: 10.7326/M20-6306. - DOI - PMC - PubMed
    1. Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. Nat Commun. 2020;11(1):4507. doi: 10.1038/s41467-020-18272-4. - DOI - PMC - PubMed
    1. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 infections, symptomatic infections, hospitalizations, and deaths using seroprevalence surveys. JAMA Netw Open. 2021;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706. - DOI - PMC - PubMed
    1. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection. Accessed May 5, 2021. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Seroepide...

Publication types